These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34087498)

  • 1. Development of peptide epoxyketones as selective immunoproteasome inhibitors.
    Li X; Hong D; Zhang M; Xu L; Zhou Y; Li J; Liu T
    Eur J Med Chem; 2021 Oct; 221():113556. PubMed ID: 34087498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
    Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
    Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of N, C-capped di- and tripeptides as selective immunoproteasome inhibitors.
    Nan G; Huang L; Li Y; Yang Y; Yang Y; Li K; Lai F; Chen X; Xiao Z
    Eur J Med Chem; 2022 Apr; 234():114252. PubMed ID: 35286927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
    Zhang W; Wang X; Zhang H; Wen T; Yang L; Miao H; Wang J; Liu H; Yang X; Lei M; Zhu Y
    Bioorg Med Chem; 2021 Jun; 40():116182. PubMed ID: 33971487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a new class of proteasome inhibitors with an epoxyketone warhead: Rational hybridization of non-peptidic belactosin derivatives and peptide epoxyketones.
    Kawamura S; Unno Y; Asai A; Arisawa M; Shuto S
    Bioorg Med Chem; 2014 Jun; 22(12):3091-5. PubMed ID: 24814885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of isoquinolinone derivatives as immunoproteasome inhibitors.
    Ettari R; Iraci N; Di Chio C; Previti S; Danzè M; Zappalà M
    Bioorg Med Chem Lett; 2022 Jan; 55():128478. PubMed ID: 34838650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells.
    Ettari R; Pallio G; Pizzino G; Irrera N; Zappalà M; Maiorana S; Di Chio C; Altavilla D; Squadrito F; Bitto A
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1307-1313. PubMed ID: 31307247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors.
    Singh PK; Fan H; Jiang X; Shi L; Nathan CF; Lin G
    ChemMedChem; 2016 Oct; 11(19):2127-2131. PubMed ID: 27561172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors.
    Maccari R; Ettari R; Adornato I; Naß A; Wolber G; Bitto A; Mannino F; Aliquò F; Bruno G; Nicolò F; Previti S; Grasso S; Zappalà M; Ottanà R
    Bioorg Med Chem Lett; 2018 Feb; 28(3):278-283. PubMed ID: 29292224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
    de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS
    J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
    Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P
    Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
    Lee MJ; Bhattarai D; Yoo J; Miller Z; Park JE; Lee S; Lee W; Driscoll JJ; Kim KB
    J Med Chem; 2019 May; 62(9):4444-4455. PubMed ID: 30964987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
    Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
    Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
    Zhao Y; Xu L; Zhang J; Zhang M; Lu J; He R; Xi J; Zhuang R; Li J; Zhou Y
    Bioorg Med Chem; 2021 Jan; 29():115867. PubMed ID: 33223460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
    Yu J; Xu L; Hong D; Zhang X; Liu J; Li D; Li J; Zhou Y; Liu T
    Eur J Med Chem; 2019 Jan; 161():543-558. PubMed ID: 30391816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors.
    Yang Y; Wang K; Wu B; Yang Y; Lai F; Chen X; Xiao Z
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127508. PubMed ID: 32853683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, and Biological Activity of Isosyringolin A.
    Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
    Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes.
    Xin BT; de Bruin G; Huber EM; Besse A; Florea BI; Filippov DV; van der Marel GA; Kisselev AF; van der Stelt M; Driessen C; Groll M; Overkleeft HS
    J Med Chem; 2016 Aug; 59(15):7177-87. PubMed ID: 27438186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
    Downey-Kopyscinski S; Daily EW; Gautier M; Bhatt A; Florea BI; Mitsiades CS; Richardson PG; Driessen C; Overkleeft HS; Kisselev AF
    Blood Adv; 2018 Oct; 2(19):2443-2451. PubMed ID: 30266819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Minimal β-Lactone Fragment for Selective β5c or β5i Proteasome Inhibitors.
    Groll M; Korotkov VS; Huber EM; de Meijere A; Ludwig A
    Angew Chem Int Ed Engl; 2015 Jun; 54(27):7810-4. PubMed ID: 25973989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.